Literature DB >> 15249757

Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life.

K Allegaert1, V Cossey, J P Langhendries, G Naulaers, C Vanhole, H Devlieger, B Van Overmeire.   

Abstract

The aim of this study was to assess the effects of intravenous co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin during the first days of life in preterm infants. The pharmacokinetics of amikacin were retrospectively calculated in a cohort of 73 neonates (gestational age <31 weeks) who received either ibuprofen-lysine or placebo following inclusion in the multicentre ibuprofen prophylaxis study. Assuming a one-compartment model with instantaneous input and first-order output, there was no significant difference in the median distribution volume (0.63 vs. 0.59 liters/kg), but the median serum half-life (16.4 vs. 12.4 h) of amikacin was significantly longer (p <0.02), and the clearance (0.36 vs. 0.6 ml/kg/min; p <0.005) of amikacin was significantly lower in infants who received ibuprofen-lysine. We conclude that the time interval between consecutive amikacin administrations should be prolonged, if ibuprofen-lysine is co-administered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249757     DOI: 10.1159/000079618

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  18 in total

1.  The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age.

Authors:  Karel Allegaert; Veerle Cossey; Anne Debeer; Jean Paul Langhendries; Bart Van Overmeire; Jan de Hoon; Hugo Devlieger
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

2.  Limited predictability of amikacin clearance in extreme premature neonates at birth.

Authors:  Karel Allegaert; Brian J Anderson; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

3.  Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis.

Authors:  Catherine M T Sherwin; Sofia Svahn; Antje Van der Linden; Roland S Broadbent; Natalie J Medlicott; David M Reith
Journal:  Eur J Clin Pharmacol       Date:  2009-03-21       Impact factor: 2.953

4.  Individualised dosing of amikacin in neonates.

Authors:  Catherine M T Sherwin; Roland S Broadbent; Natalie J Medlicott; David M Reith
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

5.  Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates.

Authors:  K Allegaert; I Scheers; E Adams; G Brajanoski; V Cossey; B J Anderson
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

6.  Common clinical and practical questions on the use of intravenous Ibuprofen lysine for the treatment of patent ductus arteriosus.

Authors:  Bart Van Overmeire
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

7.  Quantification of amikacin in bronchial epithelial lining fluid in neonates.

Authors:  C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

8.  Impact of gestational age and birth weight on amikacin clearance on day 1 of life.

Authors:  Michiel F Schreuder; Abraham J Wilhelm; Arend Bökenkamp; Simone M H Timmermans; Henriette A Delemarre-van de Waal; Joanna A E van Wijk
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 8.237

Review 9.  Clinical pharmacokinetics of aminoglycosides in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Eur J Clin Pharmacol       Date:  2008-12-23       Impact factor: 2.953

10.  Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?

Authors:  John N van den Anker; Karel Allegaert
Journal:  Eur J Clin Pharmacol       Date:  2009-07-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.